QUIDELORTHO CORP
QDELNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $8.06 β $35.58
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 68.6M
- Next Earnings
- 2027-02-09
Fundamentals Snapshot
- Annual Revenue
- $2.73B
- Last Q Revenue
- $619M
- P/E Ratio
- -1.5
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-5.37
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.9%
QUIDELORTHO CORP
QDELAbout QUIDELORTHO CORP
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

QuidelOrtho Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of QuidelOrtho Corporation - QDEL
NEW ORLEANS, Nov. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

QuidelOrtho (QDEL) Securities Investigation Notice - Levi & Korsinsky
QuidelOrtho (QDEL) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Nov. 16, 2026 QuidelOrtho shares fell roughly 14% after third-quarter

Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving QuidelOrtho (QDEL)
Point-of-Care revenue down 27% and total sales down roughly 12% year over year: QuidelOrtho's third-quarter 2026 revenue miss against Wall Street consensus sent shares down approximately 14% Point-of-Care revenue down 27

QDEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving QuidelOrtho
QuidelOrtho's May 2026 quarterly report said China's volume-based procurement program would not likely have a material impact on total annualized revenue. Third-quarter 2026 results showed China revenue down 45%, and QDE

QuidelOrtho Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into QuidelOrtho (QDEL)
QuidelOrtho narrowed its full-year revenue outlook and announced a restructuring program with its third-quarter 2026 results, and shares fell roughly 14%. QDEL shareholders who lost money have rights, and Levi & Korsinsk